Cefdinir Treatment for Acute Otitis Media

First-Line Treatment Hierarchy

The American Academy of Pediatrics recommends high-dose amoxicillin (80-90 mg/kg/day) as the gold standard initial treatment for acute otitis media due to its effectiveness against common bacterial pathogens, safety profile, low cost, acceptable taste, and narrow microbiologic spectrum 1, 2, 3
For patients who have received amoxicillin in the previous 30 days or those with concurrent conjunctivitis, high-dose amoxicillin-clavulanate (90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate in 2 divided doses) should be initiated instead 1, 2

Cefdinir is appropriate for children with non-Type I penicillin hypersensitivity reactions (such as rash, not anaphylaxis) 1, 3, 4
The cross-reactivity risk between penicillins and second/third-generation cephalosporins like cefdinir is negligible (approximately 0.1%) due to distinct chemical structures, making cefdinir highly unlikely to cause allergic reactions in penicillin-allergic patients 1
If the patient fails to respond to initial amoxicillin therapy within 48-72 hours, cefdinir can be used as an alternative agent 3, 4

The American Academy of Pediatrics recommends pediatric dosing of 14 mg/kg/day administered either once daily or in 2 divided doses 1, 2

Cefdinir showed 72% eradication rates for recurrent AOM attributable to H. influenzae 1

If no improvement occurs after 48-72 hours of cefdinir therapy, reassess the diagnosis to confirm AOM and exclude other causes of illness 3, 4
Switch to high-dose amoxicillin-clavulanate (90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate) if no improvement occurs after 48-72 hours of cefdinir therapy 1, 2
Consider ceftriaxone (50 mg IM or IV for 3 days) as an alternative if no improvement occurs after 48-72 hours of cefdinir therapy 1, 2

Distinguish between Type I hypersensitivity reactions (anaphylaxis, angioedema) and non-serious reactions (rash) when assessing penicillin allergy—cefdinir is safe for the latter but not recommended for true Type I reactions 1, 4

The American Academy of Family Physicians recommends cefdinir 14 mg/kg/day once daily or in 2 divided doses for 10 days as an alternative to penicillin in patients with non-Type I penicillin allergy 5
The Clinical Microbiology and Infection society suggests cefuroxime axetil 30 mg/kg/day in 2 divided doses for 10 days as a treatment option for acute otitis media 6, 5

For patients who have recently used amoxicillin or have concurrent purulent conjunctivitis, the Clinical Microbiology and Infection society recommends high-dose amoxicillin-clavulanate 90 mg/kg/day of amoxicillin with 6.4 mg/kg/day of clavulanate in 2 divided doses 6
The American Academy of Family Physicians recommends cefuroxime axetil 30 mg/kg/day in 2 divided doses for 10 days as a second-line treatment option 6, 5

In vitro activity: Cefdinir shows comparable activity to second‑generation cephalosporins against Streptococcus pneumoniae and similar activity to cefuroxime axetil against Haemophilus influenzae, but it is less active than cefpodoxime proxetil against H. influenzae in pediatric isolates. (American Academy of Otolaryngology‑Head and Neck Surgery) 7
Coverage of S. pneumoniae: Against penicillin‑susceptible strains, cefdinir provides good activity that is comparable to cefuroxime axetil and cefpodoxime proxetil; however, it lacks clinically significant activity against drug‑resistant S. pneumoniae (DRSP). (American Academy of Otolaryngology‑Head and Neck Surgery) 7
Coverage of H. influenzae: Cefdinir demonstrates high susceptibility rates (≈ 97–99 %) and retains activity against beta‑lactamase‑producing H. influenzae isolates. (American Academy of Otolaryngology‑Head and Neck Surgery) 7

Palatability advantage: The oral suspension of cefdinir is reported to have superior taste and palatability compared with other oral antimicrobials, which improves acceptance in children with acute otitis media. (American Academy of Otolaryngology‑Head and Neck Surgery) 7

Inadequate coverage of DRSP: In regions where penicillin‑resistant S. pneumoniae prevalence is high, cefdinir may not provide sufficient antimicrobial coverage, limiting its usefulness as empiric therapy for acute otitis media. (American Academy of Otolaryngology‑Head and Neck Surgery) 7

In children with acute otitis media, a head‑to‑head clinical trial published in the official journal of the American Academy of Otolaryngology‑Head and Neck Surgery demonstrated that cefdinir at 14 mg/kg/day for 5 days was inferior to amoxicillin‑clavulanate 80 mg/kg/day for 10 days, with cure rates of 71 % versus 86.5 % (p = 0.001) based on validated otoscopy outcomes. This evidence is classified as Level II comparative effectiveness data. 8